Effectiveness of angionten II receptor blocker (ARB), candesartan, in the treatment of hormone refractory prostate cancer (HRPC).

被引：0
|
作者：
Uemura, H [1 ]
Miyoshi, Y [1 ]
Ishiguro, H [1 ]
Nakaigawa, N [1 ]
Noguchi, K [1 ]
Kubota, Y [1 ]
机构：
[1] Yokohama City Univ, Grad Sch Med, Yokohama, Kanagawa 232, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4614
引用
收藏
页码：410S / 410S
页数：1
相关论文
共 50 条
  • [1] Metronomic chemotherapy for hormone refractory prostate cancer (HRPC)
    Hoshi, S.
    Numahata, K.
    Hoshi, K.
    Suzuki, K.
    Ono, K.
    Sugano, O.
    Ihidoya, S.
    Saito, S.
    Arai, Y.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] SYMPTOM PREVALENCE IN HORMONE REFRACTORY PROSTATE CANCER (HRPC)
    Romanus, D.
    Oh, W. K.
    Cook, F. E.
    Weeks, J. C.
    [J]. VALUE IN HEALTH, 2008, 11 (06) : A487 - A487
  • [3] Novel biological agents for the treatment of hormone-refractory prostate cancer (HRPC)
    Papatsoris, AG
    Karamouzis, MV
    Papavassiliou, AG
    [J]. CURRENT MEDICINAL CHEMISTRY, 2005, 12 (03) : 277 - 296
  • [4] Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer
    Uemura H.
    Hasumi H.
    Kawahara T.
    Sugiura S.
    Miyoshi Y.
    Nakaigawa N.
    Teranishi J.-I.
    Noguchi K.
    Ishiguro H.
    Kubota Y.
    [J]. International Journal of Clinical Oncology, 2005, 10 (6) : 405 - 410
  • [5] Phase I/II study of weekly docetaxel and vinblastine in the treatment of hormone-refractory prostate cancer (HRPC).
    Ackler, JR
    Tester, WJ
    Leighton, JC
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 771S - 771S
  • [6] Predictive modelling in hormone-refractory prostate cancer (HRPC)
    Bellmunt, Joaquim
    Carles, Joan
    Albanell, Joan
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2009, 11 (02): : 82 - 85
  • [7] Predictive modelling in hormone-refractory prostate cancer (HRPC)
    Joaquim Bellmunt
    Joan Carles
    Joan Albanell
    [J]. Clinical and Translational Oncology, 2009, 11 : 82 - 85
  • [8] New treatment strategies in the management of hormone refractory prostate cancer (HRPC): Only chemotherapy?
    Sciarra, Alessandro
    Salciccia, Stefano
    [J]. EUROPEAN UROLOGY, 2007, 52 (04) : 945 - 947
  • [9] NAVELBIN AS A SECOND LINE TREATMENT FOR PATIENTS WITH HORMONE-REFRACTORY PROSTATE CANCER (HRPC)
    Jana, J. K.
    Rovny, A. R.
    Divisova, K. D.
    Filipensky, P. F.
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (06) : 658 - 659
  • [10] Hormone-refractory prostate cancer (HRPC): Results of treatment with oral cyclophosphamide (CTX)
    Nogueira-Costa, R
    Duarte, RC
    Ramos, LAG
    Bretas, FFH
    Bicalho, OJ
    [J]. EUROPEAN JOURNAL OF CANCER, 1999, 35 : S349 - S350
12345